Do Brain Metastases Rule Out Immunotherapy in RCC?

Leggi l'articolo originale


An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases.

Lascia un commento